Obinutuzumab

Obinutuzumab (GA101) a novel glycoengineered Type II CD20 humanized IgG1 monoclonal antibody in development for non-Hodgkin lymphoma.
Read more
€0.00 (tax incl.)
Reference:
HY-P9910
Product Details
HY-P9910

Data sheet

Size
Multiple sizes
Reactivity
CD20
Application
Cancer-programmed cell death
CAS
949142-50-1

Menu

Settings